Delivering Superior Signal Clarity

On a mission to end reliance on mixed signals and reading between the lines, BioSig Technologies understands that greater clarity breeds opportunity for a new standard in cardiac care.

Learn More

Beyond the Status Quo

As physician advocates, we develop technology that provides greater clarity and opens doors to ingenious treatment solutions for the most challenging arrhythmias. We collaborate with physicians, experts, and healthcare leaders to align on the advancements that can be realized in the field of electrophysiology.

We are driven by a commitment to provide innovative solutions that elevate the standard of care. Our engineers are constantly in search of what’s possible in signal acquisition and the field of electrophysiology, driving the evolution of our technology for the physicians we serve.

An Innovation in One of the Most Critical Areas of Electrophysiology

The PURE EP™ Platform applies a unique combination of hardware and software to accurately capture intracardiac signals with unprecedented clarity and precision. By viewing pure signals that are absent of saturation, interference, or noise from other medical equipment, physicians can respond to even the most complex cardiac arrhythmias with insight-based, highly targeted cardiac ablation procedures.

Discover the PURE EP™ Platform

MEETING THE NEED TO IMPROVE ARRHYTHMIA TREATMENT

"If we improve the fidelity of our [signal] recordings, we can potentially improve the efficiency and safety of our procedures. In that respect, the PURE EP™ System is really a breath of fresh air in this field."

- Hicham El Masry, M.D. (Mayo Clinic, Arizona)
Leveraging EGMs to Improve Efficacy, Safety of Ablation Kansas City Heart Rhythm Symposium (KCHRS) 2022

Discover BioSig

BioSig is on the leading edge of digital signal processing in healthcare. Join us on the front lines to unlock the future of cardiac treatment and help transform healthcare.

Join Our Team

Company

BioSig is an advanced signal processing company delivering unmatched accuracy and precision to intracardiac signal visualization, and enhancing the treatment of arrhythmias.

Learn more about BioSig

Leadership

By uniting the diverse talents and collective experiences of industry experts, we are determined to break down barriers and go beyond our comfort zone in pursuit of unconventional solutions that advance medical technology and make a lasting impact.

Careers

BioSig is on the leading edge of digital signal processing in healthcare. Join us on the front lines to unlock the future of cardiac treatment and help transform healthcare.

Join our team

Insights

With the superior, real-time visualization of arrhythmias, PURE EP™ is paving the way for personalized patient care and breakthrough innovations in the field of electrophysiology. View the latest cases, presentations, and papers.

News & Stories

BioSig Technologies, Inc. and Streamex Exchange Corporation Announce Definitive Agreements for up to $1.1B USD in Growth Financing to Launch Gold Backed Treasury Management Strategy and to Rapidly Expand RWA Tokenization for the Commodities Markets

July 07, 2025

BioSig Technologies, Inc. (Nasdaq: BSGM), which recently merged with Streamex Exchange Corporation ('Streamex') to become one of largest public holders of gold bullion.

BioSig & Streamex Appoint Parcl Co-Founders Trevor Bacon and Kellan Grenier as Strategic Advisors

June 09, 2025

Frank Giustra ' Strategic Investor and Advisor on Commodities Founder of Wheaton Precious Metals ($37B) Founder of GoldCorp (Acquired by Newmont for $57B) Founder of LionsGate Films ($2B)

BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor

June 04, 2025

Frank Giustra - Strategic Investor and Advisor on Commodities. Founder of Wheaton Precious Metals ($37B) Founder of GoldCorp (Acquired by Newmont for $57B) Founder of LionsGate Films ($2B).